Study of the −429 T/C and −374 T/A Receptor For Advanced Glycation End Products Promoter Polymorphisms in Diabetic and Nondiabetic Subjects With Macrovascular Disease
- Barry I. Hudson, PHD ,
- Max H. Stickland ,
- T. Simon Futers, PHD and
- Peter J. Grant, MD, FRCP
- Academic Unit of Molecular Vascular Medicine, University of Leeds, Leeds General Infirmary, Leeds, United Kingdom
The receptor for advanced glycation end products (RAGE) has been implicated in the development of vascular complications of diabetes by both in vitro and in vivo studies (1). The most compelling evidence demonstrated that blocking of AGE/RAGE binding prevented atherosclerotic development in animal models (2). It is plausible that genetic differences in the RAGE gene could alter expression and function to affect disease development. In previous studies, we have identified a number of potentially functional polymorphisms: Gly82Ser in the AGE-binding domain (3) and two common promoter polymorphisms at positions −429 and −374 (4). The Gly82Ser polymorphism was not found to relate …
